NVO

Business Context and Reporting Period

Company: Novo Nordisk A/S
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2008
Accounting Standards: International Financial Reporting Standards (IFRS)
Currency: Danish Kroner (DKK)

Novo Nordisk is a global healthcare company and a world leader in diabetes care, with operations in approximately 80 countries. The company operates through two primary segments: Diabetes Care (approx. 73% of sales) and Biopharmaceuticals (hemostasis, growth hormone, and hormone replacement therapy). The company is headquartered in Bagsværd, Denmark, and employs approximately 26,600 people.

Key Financial Metrics (2008)

Liquidity Position: As of December 31, 2008, financial resources totaled DKK 17,184 million, comprising DKK 8,726 million in cash and cash equivalents, DKK 997 million in bonds, and DKK 7,451 million in undrawn committed credit facilities.

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased by 8.9% to DKK 45,553 million, driven by volume growth in diabetes care and biopharmaceuticals.
• Profitability Surge: Operating profit rose significantly by 38.4% to DKK 12,373 million, and net profit increased by 13.2% to DKK 9,645 million.
• Cost Management: R&D costs decreased by DKK 0.5 billion year-over-year, partly due to the discontinuation of pulmonary diabetes projects (non-recurring cost of DKK 0.3 billion in 2008 vs. DKK 1.3 billion in 2007).
• Cash Flow Improvement: Operating cash flow increased by 28.9% to DKK 12,863 million, attributed to stronger operating performance and working capital improvements.
• Capital Expenditure: Net capital expenditure decreased to DKK 1.7 billion from DKK 2.3 billion in 2007, reflecting the completion of major investments in Denmark, the U.S., and Brazil.

Guidance, Outlook, and Risks

Outlook for 2009:

• Management expects to invest approximately DKK 3.0 billion in fixed assets in 2009, primarily for a new filling site in China.
• The company anticipates the launch of liraglutide (a GLP-1 analogue) in 2009 following regulatory filings in the US, Japan, and Europe.
• Growth drivers include the transition from human to modern insulins, new delivery devices, and market share gains in diabetes care.

Dividend Policy:

• The Board proposed a dividend of DKK 6.00 per share for the 2008 fiscal year, to be voted on at the Annual General Meeting in March 2009.

Risks and Contingencies:

• Patent Expirations: Patents for modern insulins expire in 2011 and beyond; Prandin/NovoNorm patents expire in 2009, potentially exposing sales to generic competition.
• Regulatory Environment: Dependence on government approvals (FDA, EMA) and reimbursement policies. Pressure on healthcare costs globally may impact pricing.
• Foreign Exchange: Significant exposure to USD, JPY, and GBP fluctuations, as sales are largely in foreign currencies while costs are in DKK.
• Legal Proceedings: Reference is made to Note 36 of the Annual Report for details on ongoing legal proceedings.

Investor Verification Checklist

• Patent Portfolio: Verify the timeline for patent expirations on key products (Prandin/NovoNorm in 2009, modern insulins in 2011+) and the pipeline status of liraglutide.
• Share Repurchase Program: Confirm the status of the DKK 18.5 billion share buyback program, which was active throughout 2008 and expected to finalize by end of 2009.
• Capital Allocation: Review the DKK 3.0 billion planned investment for 2009, specifically the new facility in Tianjin, China.
• Related Party Transactions: Note the purchase of DKK 1.0 billion in B shares from Novo A/S (a related party) in 2008 as part of the buyback program.
• Non-GAAP Measures: Review the reconciliation of "Free Cash Flow" and "Return on Invested Capital (ROIC)" in the Annual Report to understand management's performance metrics.